
Bone marrow necrosis in a patient with non-Hodgkin lymphoma

Dilek ARGON¹, Mustafa ÇETİNER¹, Cafer ADIGÜZEL¹, Işık KAYGUSUZ¹,
Tülin F. TUĞLULAR¹, Tülay TECİMER², Mahmut BAYIK¹

¹ Department of Hematology, Marmara University Medical Faculty,

² Department of Pathology, Marmara University Medical Faculty, Istanbul, TURKEY

Turk J Haematol 2004;21(2): 97-100

Received: 31.10.2003 **Accepted:** 23.03.2004

ABSTRACT

Bone marrow necrosis is a rare but ominous finding in various malignant and nonmalignant disorders. It is usually a postmortem diagnosis, but with the advent of modern imaging methods and clinical suspicion, bone marrow necrosis can be diagnosed as antemortem, especially in malignant disorders. We report a 60-years old man with newly diagnosed non-Hodgkin lymphoma presenting with anemia and very high level of alkaline phosphatase. On bone marrow biopsy, it was noted with extensive BMN characterized by cellular debris with indistinct cellular margin and abnormally eosinophilic staining cytoplasm. Despite the prompt institution of aggressive chemotherapy, one week later, liver function tests gradually deteriorated and the patient succumbed. Given the high mortality rate, when the bone marrow necrosis is suspected especially in a patient with malignancy, disease specific treatment and vigorous supportive measures should be immediately commenced.

Key Words: Bone marrow necrosis, Hematologic malignancy.

ÖZET

Non-Hodgkin lenfomalı bir hastada kemik iliđi nekrozu

Kemik iliđi nekrozu nadir görölen, kötü prognozlu bir klinik tablodur. Tümöral ve tümör dıřı çeřitli nedenlerle oluřmakla beraber en sık lösemilerde karřılařılmaktadır. Sunulan olgu, 60 yařında anemi, iki taraflı servikal lenfadenopatileri ve hepatosplenomegalisi olan, kan tetkiklerinde çok yüksek alkalin fosfataz seviyesi, kemik iliđi biyopsisinde silüet řeklinde tipik hücre boyanması ile karakterize görünümlü yaygın kemik iliđi nekrozu saptanan ve agresif tedaviye rađmen kaybedilen Hodgkin-dıřı lenfomalı bir hastadır. Bu tip hastaların sađaltımında erken tanının, yođun bir destek tedavisinin ve altta yatan nedene yönelik agresif tedavinin önemini vurgulamak istiyoruz.

Anahtar Kelimeler: Kemik iliđi nekrozu, Hematolojik malignite.

INTRODUCTION

Although it has been described sixty years ago, little is known on bone marrow necrosis (BMN) in medical practice^[1]. The first antemortem definition was made by Nies in patients with acute leukemia in 1965^[2]. BMN is defined as necrosis of myeloid tissue and medullary stroma in large areas of the bone marrow (BM)^[3]. This clinicopathologic entity is completely different from both avascular bone necrosis in which there is no destruction of spicular architecture and marrow aplasia in which there is only a loss of myeloid tissue not reticular structure^[4,5]. By now, about 270 cases have been reported in the literature. Table 1 lists all causes of BMN that has reported so far. Malignancy which constitutes 90% of cases is the most common underlying disorder of BMN^[3,6]. Up to 10% of patients with BMN have nonmalignant disorders. As shown in Table 1, there is a wide variety of disorders causing BMN.

The most important diagnostic sign is bone pain^[7]. The pain is acute, intense and usually located in lower back. It is more evident in malignant disorders. More than half of patients with BMN present with fever^[7]. Embolization of fat and necrotic marrow to lung are the other rare but life-threatening complications of BMN^[8]. Among the laboratory findings, various cytopenias, leukoerythroblastic differential count, and increased levels of lactic dehydrogenase (LDH) and alkaline phosphatase (AP) are the most prominent features^[9]. In BM examination, it is noted that the cells lose their normal staining pattern and have irregular shape and margin on cytology^[3]. It is usually required to aspirate the marrow from multiple sites to obtain enough material^[10]. The combination of gelatinous transformation and necrosis is the hallmark of BM biopsy^[11]. Adjunctive to clinicopathologic diagnose, BM scintigraphy with Technetium and indium is a highly sensitive method. Magnetic resonance imaging is another useful noninvasive diagnostic tool, though its sensitivity not superior to scintig-

Table 1. Associated disorders in BMN

Disorders	%
Malignant disorders	91
Hematologic malignancies	60
Acute leukemias	
Chronic myeloproliferative disorders	
Lymphomas	
Solid tumors	31
Unknown primary tumors	
Breast	
Lung	
Ovary	
Prostate	
Esophagus and stomach	
Neuroblastoma/medulloblastoma	
Carsinoid	
Nonmalignant disorders	9
Infections	
Drugs	
Sickle cell disease	
Others	
Hyperparathyroidism	
Anorexia nervosa	
Hemolytic uremic syndrome	
Antiphospholipid syndrome	
DIC	
Idiopathic	

raphy. Both methods are useful in the monitoring of the recovery period^[12,13].

A CASE REPORT

A 60-years old man was referred by his family physician to the Department of Hematology of Marmara University complaining with anorexia, weight loss, itching, and intermittent mild fever. On examination, he was noted to have a pale appearance. He was afebrile, the lungs and heart examination were normal. Abdominal examination revealed moderate hepatosplenomegaly. Among his peripheral lymph nodes, cervical, supraclavicular, axillary and inguinal nodes were

palpable bilaterally. There was no cyanosis, jaundice, dyspnea or edema. His past medical history was significant for coronary heart disease. He was taking a vasodilator, an angiotensin converting enzyme inhibitor and aspirin. He had no history of surgical intervention.

Complete blood cell analysis revealed mild anemia with normocytic normochrom appearance (Hb: 9.9 g/dL), and lymphocytosis. Erythrocyte sedimentation rate was 22 mm/h. In biochemical analysis the most prominent finding was the increased level of AP (2758 mg/dL). LDH and transaminase levels also had increased minimally. All the other biochemical parameters were normal.

At the end of first part of diagnostic work-up, the patient was thought to have a kind of lymphoma and referred to surgery unit for excisional biopsy of one of the enlarged cervical nodes. Cervical node biopsy revealed diffuse large B-cell lymphoma. Then, the patient underwent bone marrow biopsy and toracoabdominal and cervical axial computerized tomography (CT) for staging purpose. CT scan of body revealed mediastinal and para-aortic lymphadenomegalies in addition to peripheral enlarged nodes. BM aspiration resulted in dry-tap. On examination of BM biopsy, it was noted extensive BMN characterized by cellular debris with indistinct cellular margin and abnormally eosinophilic staining cytoplasm (Figure 1).

At the completion of diagnostic studies, the patient was diagnosed to have stage IVB diffuse large B-cell lymphoma and treated with aggressive chemotherapy. Despite chemotherapy, one week later, liver function tests gradually deteriorated and the patient succumbed.

DISCUSSION

Although the survival of BMN depends on the underlying disorder, the ultimate prognosis is poor^[14]. Table 2 lists survival rates in various disorders^[3]. In hematologic malignancy, especially leukemias, most of the pa-




Figure 1. Bone marrow necrosis (H&E stain 400x).

Table 2. Survival rates in BMN

Disorder	n	Median survival (mo)
ALL	35	4
AML	25	2
Lymphoma	24	1
MPD	7	3
Solid tumors	18	5 weeks
Infections	5	3 weeks
Others	5	2.5 weeks

MPD: Myeloproliferative disorders.

tients with BMN in whom achieved complete remission usually relapse early^[15,16]. BMN in solid tumors reflects widespread metastasis including bone marrow and bad outcome. Despite the notorious outcome, some authors have reported resolved patients with chemotherapy and supportive measures even if, rare. For this reason, when an underlying pathology is detected, vigorous supportive care together with special treatment must be started including transfusion of blood components, adequate antibiotic treatment, hydration, oxygenation and alkalinization to permit a time for spontaneous recovery of the normal hematopoiesis. Given the complex pathophysiology of BMN, some novel therapies such as anti tumor necrosis factor (TNF)- α antibodies and various cytokines may be promising modalities in future.

REFERENCES

1. Wade L, Stevenson L. Necrosis of bone marrow with fat embolism in sickle cell anemia. *Am J Pathol* 1941; 17:47-54.
2. Nies BA, Kundel DW, Thomas LB, et al. Leukopenia, bone pain, and bone necrosis in patients with acute leukemia. *Ann Intern Med* 1965;62:698-705.
3. Janssens AM, Offner FC, Van Hove WZ. Bone marrow necrosis. *Cancer* 2000;15:1769-80.
4. Hughes RG, Islam A, Lewis SM, et al. Spontaneous remission following bone marrow necrosis in chronic lymphocytic leukemia. *Clin Lab Haematol* 1981; 3:173-84.
5. Smith RR, Spivak JL. Marrow cell necrosis in anorexia nervosa and involuntary starvation. *Br J Haematol* 1985;60:525-30.
6. Paydas S, Ergin M, Baslamisli F, et al. Bone marrow necrosis: clinicopathologic analysis of 20 cases and review of the literature. *Am J Hematol* 2002;70: 300-5.
7. Pennaforte JL, Dufour M, Etienne JC, et al. Diagnostic problems in bone marrow necrosis. Report of a case revealing acute leukemia. *Arch Anat Cytol Pathol* 1986;34:111-6.
8. Bermejo A, Gonzales FA, Villegas A, et al. Bone marrow necrosis. *Am J Hematol* 1995;50:65-6.
9. Kiraly JF, Wheby MS. Bone marrow necrosis. *Am J Med* 1976;60:361-8.
10. Norgard MJ, Carpenter JT, Conrad ME. Bone marrow necrosis and degeneration. *Arch Intern Med* 1979;139:905-11.
11. Kundel D, Brecher G, Bodey G, et al. Reticulin fibrosis and bone infarction in acute leukemia. Implications for prognosis. *Blood* 1964;23:526-44.
12. Musto P, La Sala A. Again about bone marrow necrosis: particular diagnostic aspects. *Hematol Pathol* 1989;3:185-7.
13. Weissman DE, Negendank WG, Al-Katibb AM, et al. Bone marrow necrosis in lymphoma studied by magnetic resonance imaging. *Am J Hematol* 1992; 40:42-6.
14. Ranaghan L, Morris TC, Desai ZR, et al. Bone marrow necrosis. *Am J Hematol* 1994;47:225-8.
15. Kunieda Y, Okabe M, Kunita Y, et al. Bone marrow necrosis in thymic T-cell lymphoma. *Rinsho Ketsueki* 1990;31:492-6.
16. Uoshima N, Yamazaki N, Linuma S, et al. Acute unclassified leukemia with bone marrow necrosis. *Rinsho Ketsueki* 1991;32:61-6.

Address for Correspondence:

Dilek ARGON, MD

Doğancılar Halkdersanesi Sokak, No: 27/1
81160, Üsküdar, İstanbul, TURKEY

e-mail: d_argon@hotmail.com